Sourcing Standard: 503A Compounding Pharmacy Required for Pharmaceutical-Grade Peptides
The speaker specifies that pharmaceutical-grade peptides from a 503A compounding facility represent the appropriate sourcing standard for this protocol. This regulatory designation (FDA-recognized compounding pharmacies) is presented as the benchmark for purity and dosing reliability. No specific dosages are mentioned, but 'therapeutic doses' are referenced in the clinical context.
Safety Warning: Gray Market Research Chemicals Pose Purity and Safety Risks
The speaker explicitly warns against using gray market research chemicals, stating they produce inconsistent results and have in some cases sent people to the emergency room. Dosing accuracy, purity, and sourcing are identified as equally important as the protocol itself. This constitutes a direct safety contraindication against non-pharmaceutical-grade sourcing.
Complementary Mechanisms Justify Stacking: Angiogenesis + Cellular Migration
The speaker uses a road-and-traffic metaphor to explain the mechanistic rationale for the stack: BPC-157 'builds the road' (new vasculature) while TB-500 'floods it with repair cells' (cellular migration). This dual-pathway engagement is presented as the core scientific justification for combining the two peptides rather than using either in isolation.
The 'Wolverine Stack' — BPC-157 and TB-500 Combination Protocol
BPC-157 and TB-500 stacked together are referred to as the 'Wolverine stack,' described as the most researched healing peptide combination in regenerative medicine. The rationale for stacking is that the two peptides target completely different repair pathways simultaneously — angiogenesis (BPC-157) and cellular migration (TB-500) — producing a synergistic effect greater than either peptide alone. No specific dosages or dosing frequencies are provided in this segment.
TB-500 Identified as a Fragment of Thymosin Beta-4
The speaker identifies TB-500 as a fragment of thymosin beta-4, characterizing thymosin beta-4 as one of the body's primary peptides involved in immune response and tissue repair. This positions TB-500 within an endogenous biological repair system. No dosage or study citation is provided.
TB-500 Facilitates Cellular Migration and Systemic Anti-Inflammation
TB-500 is described as a fragment of thymosin beta-4, a peptide the body uses for immune response and tissue repair. Its primary claimed mechanism is facilitating cellular migration of repair cells to injury sites. It is also said to reduce inflammation systemically and accelerate tissue regeneration. No specific dosage is mentioned.
Mechanistic Differentiation: Thymosin Alpha-1 vs. Thymosin Beta-4 — Same Family, Different Roles
Despite sharing a naming convention and peptide family classification, Thymosin Alpha-1 and Thymosin Beta-4 serve fundamentally different physiological roles — immune modulation versus tissue repair, respectively. The speaker emphasizes the importance of matching the specific peptide to the specific underlying mechanism of a patient's condition, framing this as the distinction between trend-based and targeted care. No dosages, stacking protocols, or safety warnings are discussed.
Clinical Indication Matching: Thymosin Beta-4 for Injury and Surgical Recovery
Thymosin Beta-4 is recommended as the more appropriate peptide for patients recovering from physical injury, surgery, or soft tissue damage. The recommendation is based on its tissue repair mechanisms. No dosages, frequencies, or treatment durations are specified.
Thymosin Beta-4 Primary Mechanism: Tissue Repair and Regeneration
Thymosin Beta-4 is characterized as a tissue repair and regeneration peptide, distinct from its alpha counterpart. Its key mechanisms include promotion of wound healing, angiogenesis, and cellular migration. The speaker uses the framing of 'tissue repair and recovery' as its core identity.
TB4 as a Potential Treatment for Soft Tissue Injuries with Limited Blood Supply
The speaker highlights TB4 as particularly clinically interesting for soft tissue injuries such as tendons, ligaments, and muscle tears, which are notoriously slow to heal due to naturally limited blood supply. The VEGF-modulating and angiogenic properties of TB4 are implied to be especially beneficial in these low-vascularity tissues. No dosage or protocol is specified.
TB4 Modulates VEGF to Stimulate Angiogenesis at Injury Sites
TB4 is described as modulating vascular endothelial growth factor (VEGF), a signaling molecule that triggers the growth of new blood vessels into damaged tissue. This angiogenic effect is presented as critical for delivering oxygen and nutrients needed to fuel the repair process. No dosage is mentioned.
TB4 Promotes Migration of Progenitor (Stem Cell-Like) Cells to Injury Site
TB4 is described as recruiting progenitor cells — characterized as stem cell-like repair workers — to the injury site. These cells are framed as foundational to tissue rebuilding. No dosage is mentioned.
TB4 Promotes Migration of Keratinocytes to Injury Site
TB4 is stated to promote the migration of keratinocytes, the cells that form the outer skin layer, to the site of injury. This mechanism is relevant to wound closure and skin repair. No dosage is mentioned.
TB4 Promotes Migration of Endothelial Cells to Injury Site
TB4 is described as promoting the migration of endothelial cells — the cells that line blood vessels — to the site of injury. This cellular recruitment is presented as a key mechanism by which TB4 facilitates tissue repair. No dosage is mentioned.
TB4 Accelerates Tissue Repair and Wound Healing
TB4's most well-documented benefit is described as its ability to speed up tissue repair and wound healing. It is said to play a critical role specifically in the rebuilding phase of the body's three-stage repair cascade (immune cleanup, rebuilding, remodeling). No dosage information is provided in this segment.
TB4 Endogenous Spike in Response to Tissue Damage
TB4 (Thymosin Beta-4) levels naturally increase in the body when tissue is damaged due to injury, inflammation, or disease. This endogenous response suggests TB4 plays a physiologically important role in the body's repair signaling. No specific dosage is mentioned as this describes the body's natural response.
Pre-Blended vs. Individual Peptides: Convenience-Efficacy Trade-Off Assessment
The speaker concludes that pre-blended peptide products represent a modest but real trade-off: approximately 5–10% efficacy loss in exchange for the convenience of fewer injections. This loss is characterized as not a 'deal breaker' under normal usage conditions (vial finished within 20–30 days), contrary to more alarmist claims circulating on social media. The framing implies that for most practical users, the convenience benefit outweighs the marginal efficacy reduction.
Amino Acid Instability as a Key Variable in Evaluating Peptide Blend Compatibility
The speaker identifies amino acid composition as one of two primary variables when evaluating the stability of a peptide blend. Certain amino acids are inherently unstable in aqueous solution, with methionine cited as a specific example due to its susceptibility to oxidation. This principle is presented as a general framework applicable beyond just the 'Glow' blend to any pre-blended peptide product.
Storage Conditions Required to Minimize Peptide Degradation in Solution
The speaker specifies three key storage and reconstitution conditions that apply to approximately 95% of peptides in common circulation and that underpin the stability analysis: time in solution should not exceed 30 days, reconstituted peptides must be stored refrigerated with no direct UV light exposure, and BAC (bacteriostatic) water should be used for reconstitution. Deviating from these conditions would introduce additional degradation variables not accounted for in the efficacy estimates.
Time-Dependent Degradation: Blended Peptide Stability Window of 10–30 Days
The speaker asserts that degradation in pre-blended peptide vials is minimal within a 10–30 day usage window, making the copper-methionine interaction largely negligible at standard dosing. The primary concern arises when a vial is stretched to 45–60 days, at which point cumulative degradation becomes more clinically meaningful. Most users finishing a vial of 'Glow' in approximately 20 days are considered to be well within the safe stability window.
Overall Efficacy Loss Estimate for Pre-Blended Peptide Formulations (e.g., 'Glow')
When accounting for both methionine oxidation and ionic aggregation across all four peptides in the 'Glow' blend, the speaker estimates a total average efficacy loss of approximately 5–10% over 30 days. TB-500 is projected to lose 10–15%, while BPC-157, GHK-Cu, and KPV are each estimated to lose only 2–3%. This trade-off is characterized as minor relative to the convenience benefit of a pre-blended formulation.
Ionic Incompatibility and Aggregation Risk in Mixed-Charge Peptide Blends
Every peptide carries an ionic charge — some are acidic and some are basic. When peptides with opposite charges are mixed in the same vial, they can attract one another and aggregate over time, potentially reducing bioavailability and efficacy. In the 'Glow' blend specifically, BPC-157 and TB-500 are identified as acidic peptides, while GHK-Cu and KPV are identified as basic peptides, creating a theoretical aggregation risk.
Methionine Oxidation Risk in TB-500 When Blended with Copper-Containing Peptides
TB-500 contains methionine, an amino acid that is unstable in solution and prone to oxidation. When co-formulated with copper-containing peptides such as GHK-Cu, the copper can catalyze and accelerate that oxidation. This interaction is identified as the primary stability concern in pre-blended formulations containing both peptides. The speaker estimates TB-500 may lose approximately 10–15% efficacy over 30 days due to this interaction.
Peptide Triple Stack Used as Post-Stem Cell Recovery Protocol
Dr. Purita positions the BPC-157, TB-500, and GHK-Cu triple stack as part of the post-treatment recovery protocol following stem cell injections, alongside shockwave therapy and red light therapy. The combination is intended to enhance tissue repair and recovery after regenerative procedures. No specific dosages, frequencies, or duration of the peptide protocol are provided.
Safety Warning: BPC-157 and TB-500 Contraindicated in Cancer Patients
Dr. Purita explicitly warns that BPC-157 and TB-500 are 'not so good' for cancer patients, implying a potential risk of promoting tumor growth or interfering with cancer treatment. This is presented as a clinical contraindication in his practice. He contrasts these with GHK-Cu, which he considers anti-cancer. No mechanistic explanation is provided in the transcript for why these peptides are contraindicated.
Triple Peptide Stack: BPC-157, TB-500, and GHK-Cu for Tissue Healing
Dr. Purita describes a 'triple stack' of BPC-157, TB-500, and GHK-Cu (copper peptide) as a standard protocol used in his clinic to support tissue healing and recovery, particularly in the context of preparing patients for or following stem cell procedures. He refers to this combination as the 'glow stack' (a term used by others) and states it 'works exceptionally well.' No specific dosages or frequencies are mentioned in the transcript.
Lack of Regulatory Oversight in the Gray Market Peptide Industry
The speaker highlights that the gray market peptide research chemical industry operates without regulatory oversight, meaning there is no authority verifying product quality, labeling accuracy, or sterility. This systemic gap is presented as the root cause of widespread quality failures. The speaker frames this as an industry-wide problem rather than isolated incidents.
Third-Party Testing Recommendation for Gray Market Peptides
For users who choose to source peptides from unregulated gray market vendors, the speaker recommends sending vials to a third-party testing service before use to verify contents and quality. This is framed as a harm-reduction measure rather than an endorsement of gray market sourcing. No specific testing services or methodologies are named.
503B Outsourcing Facilities as the Strictest Legitimate Peptide Source
503B outsourcing facilities are identified as the second and more strictly regulated legitimate sourcing pathway for peptides, being FDA-registered. The speaker implies these carry a higher standard of quality assurance than 503A compounding pharmacies. No specific peptide products or facilities are named.
503A Compounding Pharmacy as a Legitimate Peptide Source
The speaker identifies 503A compounding pharmacies as one of two legitimate sourcing pathways for quality peptides. These facilities are state-regulated and require a valid prescription to dispense. This is presented as a safer alternative to gray market research chemical vendors.
Unit Confusion (mg vs mcg) as a Critical Dosing Safety Hazard
The speaker warns that confusion between milligrams and micrograms in peptide dosing represents a serious safety and efficacy hazard. A single misplaced decimal point can result in the difference between a therapeutic dose and a sub-therapeutic or negligible dose. No specific threshold doses are provided for either peptide.
Bacterial Contamination Risk in Unregulated Peptide Vials
The speaker identifies bacterial contamination as a documented finding in third-party testing of gray market peptide vials. This represents a direct safety risk to users who inject unregulated research chemical peptides. No specific contamination incidents, pathogens, or clinical outcomes are described.
Gray Market Peptide Quality Problem: Underdosing and Mislabeling
Third-party testing of research chemical vials has reportedly revealed significant quality control failures in the gray market peptide industry, including underdosing, receipt of a completely different peptide than what was labeled, bacterial contamination, and vials containing only saline. The speaker references a specific example of paying for 5 mg and receiving something entirely different. No specific testing studies or labs are cited by name.
Wolverine Stack (BPC-157 + TB-500) Clinical Efficacy Claim
Dr. Jones asserts that the Wolverine stack combining BPC-157 and TB-500 'absolutely works,' citing his own personal use and use among his patient population. No specific dosages, frequencies, or duration protocols are provided beyond a general 3-month run time referenced in the context of a user's failed cycle. The claim is based on clinical experience rather than cited studies.
TB-500 Modulates VEGF to Stimulate Angiogenesis at Injury Sites
TB-500 is described as modulating vascular endothelial growth factor (VEGF), a signaling molecule that triggers the growth of new blood vessels into damaged tissue. This neovascularization is presented as critical for delivering oxygen and nutrients necessary to fuel the repair process. No dosage information or study citations are provided in this excerpt.
TB-500 Acts as a Cellular 'Emergency Dispatcher' Coordinating Tissue Repair
The speaker uses an analogy to describe TB-500's role as an orchestrator of the healing response, coordinating multiple repair cell types to arrive at the injury site in a timely and organized manner. Without TB-500's signaling, repair processes are described as delayed and disorganized. This is a mechanistic framing presented without citation of specific studies.
TB-500 Promotes Migration of Repair Cells to Injury Sites
TB-500 (referred to in the transcript as 'TB4', the synthetic analog of Thymosin Beta-4) is described as promoting the migration of three key cell types to injury sites: endothelial cells, keratinocytes, and progenitor cells. This coordinated cellular recruitment is presented as central to TB-500's tissue repair mechanism. No dosage or protocol information is provided in this excerpt.
TB-500 Modulates VEGF to Stimulate New Blood Vessel Growth into Damaged Tissue
TB-500 is described as modulating vascular endothelial growth factor (VEGF), a signaling molecule that triggers the growth of new blood vessels into damaged areas. This angiogenic effect is presented as critical for delivering oxygen and nutrients necessary to fuel the tissue repair process. No dosages, study citations, or clinical trial data are referenced in this excerpt. The mechanism is framed as a key downstream effect of TB-500's action beyond simple cell recruitment.
TB-500 Promotes Migration of Endothelial Cells, Keratinocytes, and Progenitor Cells to Injury Sites
TB-500 (referred to in the transcript as 'TB4', the synthetic analog of Thymosin Beta-4) is described as promoting the migration of three key cell types to injury sites: endothelial cells (lining blood vessels), keratinocytes (forming the outer skin layer), and progenitor cells (stem cell-like repair workers). This coordinated cellular recruitment is presented as central to TB-500's tissue repair mechanism. No specific dosages or clinical trial citations are provided; the claim is presented as established mechanistic knowledge by the speaker. The city/dispatcher analogy is used to illustrate how TB-500 orchestrates organized repair versus disorganized healing in its absence.
Safety Warning: Pharmaceutical-Grade Peptides Required (503A Pharmacy)
The speaker issues a sourcing warning, stating that research-grade peptides are not equivalent to pharmaceutical-grade peptides and advising viewers to obtain peptides exclusively from a 503A compounding pharmacy. This is framed as a critical safety or quality rule. No specific data on contaminant risks or purity differences between grades is provided.
High-Dose TB-500 Protocol for Serious Injuries
For more serious injuries, the speaker describes escalating TB-500 dosing up to 2,000 micrograms, compared to the standard 500 micrograms daily. This higher dose is described as part of their clinical practice for select cases. No safety data, titration guidance, or study references are provided for this elevated dose.
Systemic Biodistribution: Injection Site Independence
The speaker claims that both BPC-157 and TB-500 work systemically, meaning injection does not need to occur directly at the injury site for the peptides to be effective. Despite this, the speaker acknowledges that injecting at the injury site is common practice, including in his own use. No pharmacokinetic studies are cited.
The Wolverine Stack: BPC-157 + TB-500 Combination Protocol
The speaker recommends combining BPC-157 and TB-500 — referred to as the 'Wolverine stack' — for nagging injuries, slow recovery, and gut issues. The standard protocol is 500 micrograms of each peptide daily for a 3-month cycle. This is presented as a clinical recommendation without citation of controlled studies.
TB-500 Mechanism of Action: Angiogenesis and Cellular Migration
TB-500 is described as promoting new blood vessel growth (angiogenesis) and improving cellular migration to damaged areas. These mechanisms are presented as complementary to BPC-157's effects. No studies are cited to support these claims.
Warning against simultaneous multi-peptide stacking
Dr. Jones warns that taking five or more peptides concurrently — a common biohacker practice — leads to wasted money and minimal results. This is framed as a safety/efficacy warning based on his clinical observations, though no adverse effects are specified beyond lack of efficacy.
Phased peptide protocol: Foundation → Healing → Optimization → Anti-Aging
Dr. Jones's clinic uses a sequential phasing approach rather than simultaneous stacking: (1) Foundation, (2) Healing, (3) Optimization, (4) Anti-aging. He warns that skipping phases wastes money and rushing the stack yields no results. No specific peptide-to-phase assignments or dosages are provided in this transcript.
Peptide sequencing order matters more than the stack composition
Dr. Jones argues that the order in which peptides are introduced matters more than which peptides are combined. He observes that people taking five peptides simultaneously (BPC-157, TB-500, GH secretagogues, fat loss peptides, anti-aging compounds) often get poor results. No dosages mentioned.
Warning: Peptides mask autoimmune root cause in lupus
Dr. Jones warns that relying on peptide therapies without addressing the underlying autoimmune drivers of lupus leads to expensive, chronic dependency on repeated peptide cycles. He argues that addressing root causes (gut health, inflammation, nutrient deficiencies, dietary triggers, nervous system) reduces the need for ongoing peptide use, making treatment more sustainable.
Lupus patients using BPC-157 and TB-500 as symptom management
Dr. Jones observes that many lupus patients are using peptide therapies like BPC-157 and TB-500 (referred to collectively with 'the Wolverine' stack) to manage joint pain and inflammation symptoms. He states he'd prefer patients use these over harmful biologics or corticosteroids, but cautions that they are still masking the underlying autoimmune problem rather than addressing root cause.
Sourcing Warning: Pharmacy-Grade vs. Research Chemical Peptides
Dr. Jones warns that peptide sourcing is more important than the peptide selection itself. He states that research-grade chemicals lack consistency and recommends only pharmacy-grade peptides. This is positioned as a safety and efficacy concern — implying that research chemicals may be underdosed, contaminated, or inconsistent in formulation.
TB-500 Mechanism: Repair Cell Recruitment
The second peptide in the stack is described as flooding the injury area with repair cells. Based on known mechanisms, this cell-migration and repair-cell recruitment property aligns with TB-500 (Thymosin Beta-4 fragment). No dosage or frequency is specified.
The Wolverine Stack: BPC-157 + TB-500 Combination for Injury Repair
Dr. Jones describes a peptide stack he calls 'The Wolverine Stack' combining BPC-157 and TB-500 for injury healing. He claims the two peptides work synergistically — one promotes angiogenesis (new blood vessel formation) into the injury site, while the other recruits repair cells to the area. No specific dosages or injection protocols are provided.
TB-500 effectiveness is determined by total weekly dose, not dosing frequency
For TB-500, the critical variable is the cumulative weekly dose rather than dosing frequency. Smaller daily doses provide comparable weekly exposure to larger twice-weekly doses. This is attributed to TB-500's intracellular mechanism where actin binding sustains activity beyond plasma clearance.
BPC-157 + TB-500 blend: twice-weekly dosing is also effective
Twice-weekly dosing of the BPC-157/TB-500 blend can also work because the TB-500 component maintains effectiveness through its intracellular mechanism regardless of frequency. However, this is suboptimal for the BPC-157 component. The speaker notes either strategy works and comes down to personal preference.
BPC-157 + TB-500 blend: daily dosing is the optimal protocol
When using a pre-made BPC-157/TB-500 blend, daily dosing is recommended. Daily administration does not reduce TB-500 effectiveness (since total weekly exposure remains comparable) while ensuring maximum BPC-157 benefit due to its presence-dependent mechanism. The blend makes daily dosing the simpler and more effective strategy.
TB-500 can be dosed twice per week when used separately
When used as a standalone peptide (not in a blend), TB-500 only needs to be administered twice per week. This less frequent dosing schedule is sufficient because its intracellular actin-binding mechanism provides sustained activity regardless of plasma clearance. What matters is the total weekly dose, not constant plasma levels.
TB-500 mechanism: intracellular actin binding for sustained tissue repair
TB-500 works by entering cells and binding to actin, a structural protein involved in tissue repair. Once bound intracellularly, TB-500 continues to promote repair processes independent of its plasma concentration. This intracellular depot effect distinguishes it from BPC-157's presence-dependent mechanism.
TB-500 has a short plasma half-life (~1-2 hours) but prolonged intracellular action
TB-500 has a plasma half-life of only 1-2 hours, similar to BPC-157. However, unlike BPC-157, TB-500 enters cells and binds to actin (a structural protein involved in repair), allowing it to continue driving tissue repair even after the peptide has cleared from the bloodstream.
BPC-157 and TB-500 Angiogenesis Is Not Cancer-Promoting
Dr. Bachmeyer briefly addresses concerns about BPC-157 and TB-500 causing cancer via angiogenesis. He states that the angiogenesis promoted by these peptides is controlled, well-regulated biological growth — not the erratic, uncontrolled growth that cancer requires. He urges listeners to 'stop and smell the biology.'
TB-500 does not cause cancer despite VEGF upregulation
Dr. Bachmeyer explicitly addresses the concern that VEGF upregulation could promote cancer, stating TB-500 does not cause cancer and is in fact anti-cancer, despite its mechanism of upregulating vascular endothelial growth factor.
TB-500 cycling requirement — cannot take daily indefinitely
Dr. Bachmeyer warns that TB-500 cannot be taken every day forever and needs to be cycled. No specific cycling protocol (on/off duration) was provided in this portion of the transcript.
TB-500 is pleiotropic — four primary mechanisms of action
TB-500 acts through four primary mechanisms simultaneously: (1) increases angiogenesis, (2) mitigates inflammation, (3) inhibits fibroblast activation and collagen deposition, and (4) promotes cardiac stem cell/progenitor cell mobilization. This pleiotropic nature addresses disease at the mechanism level rather than the symptom level.
TB-500 is based on thymosin beta-4 — a naturally occurring actin-regulating peptide
TB-500 is based on thymosin beta-4, a naturally occurring 43-amino-acid protein identified by Schroeder in 1981. It is an actin-regulating peptide that binds to actin monomers, sequesters them to prevent uncontrolled polymerization, and makes them available for controlled redeployment when cells need to rebuild or migrate.
TB-500 for atrial fibrillation and cardiac conduction problems
TB-500 is specifically mentioned as relevant for atrial fibrillation (AFib), cardiac conduction abnormalities, enlarged heart, ejection fraction problems, and ventricular problems. These are categorized as tissue damage problems requiring tissue rebuilding rather than anti-inflammatory intervention alone. No dosage or protocol details provided in the available transcript.
KPV + TB-500 stack for comprehensive cardiovascular disease resolution
The core thesis is that KPV addresses the root cause of cardiovascular disease (chronic systemic inflammation — restoring endothelial function, resolving inflammation, stabilizing plaque) while TB-500 addresses downstream tissue damage (cardiac scarring, fibrosis, structural remodeling). Together they are positioned as a comprehensive two-pronged solution. No specific dosages or protocol timing mentioned in the available transcript.
TB-500 rebuilds damaged cardiac tissue post-myocardial infarction
TB-500 is presented as a compound that literally rebuilds cardiac tissue damaged by myocardial infarction. After an MI, cardiomyocytes die via necrosis and fibroblasts lay down disorganized collagen scar tissue that cannot contract. TB-500 is positioned as the solution for existing tissue damage including scar tissue, myocardial fibrosis, ejection fraction problems, enlarged heart, and pericardium-related issues. No specific dosages mentioned in this segment.
Safety claim: cannot overdose on KPV, BPC-157, or TB-500
Dr. Bachmeyer claims that you cannot overdose and die from KPV, BPC-157, or TB-500, contrasting these with statins, NSAIDs, and prednisone which can cause fatal overdose. He argues that since the body naturally produces the parent compounds (e.g., alpha-MSH for KPV), they are inherently safer than synthetic pharmaceuticals.
TB-500 desensitization warning from oversaturation
Dr. Bachmeyer warns that taking TB-500 more frequently than its ~5-day half-life allows leads to receptor oversaturation, desensitization, and 'biology gets decimated.' He specifically states micro-dosing TB-500 (as would happen in a daily blend) just 'tickles the receptors and doesn't work.'
BPC-157, TB-500, and GHK-Cu blend criticism — incompatible half-lives
Dr. Bachmeyer argues blends of BPC-157, TB-500, and GHK-Cu are ineffective for two reasons: (1) they get corrupted inside the vial, and (2) incompatible half-lives make co-administration illogical. TB-500 has a ~5-day half-life (dosed near-weekly) while BPC-157 has a ~1-day half-life (dosed daily). You either micro-dose TB-500 (which he says just 'tickles receptors' and doesn't work) or skip days of BPC-157. He also states GHK-Cu 'demolishes' in blends (copper interaction).